Dillon & Associates Inc. Acquires 277 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Dillon & Associates Inc. raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,274 shares of the medical equipment provider’s stock after buying an additional 277 shares during the period. Intuitive Surgical comprises about 1.7% of Dillon & Associates Inc.’s holdings, making the stock its 20th largest position. Dillon & Associates Inc.’s holdings in Intuitive Surgical were worth $11,919,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Creekmur Asset Management LLC boosted its holdings in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the 2nd quarter worth $26,000. Delos Wealth Advisors LLC increased its holdings in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Godsey & Gibb Inc. increased its holdings in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the last quarter. Finally, LRI Investments LLC bought a new position in shares of Intuitive Surgical during the 1st quarter valued at approximately $30,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jamie Samath sold 22,903 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares in the company, valued at $4,597,425. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,178 shares of company stock valued at $45,897,071 in the last quarter. 0.80% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Up 0.2 %

Shares of ISRG stock opened at $537.07 on Wednesday. The stock has a market capitalization of $191.29 billion, a price-to-earnings ratio of 86.35, a P/E/G ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $281.12 and a twelve month high of $542.59. The stock has a fifty day simple moving average of $494.78 and a two-hundred day simple moving average of $453.94.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.32. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Research analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler restated an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. BTIG Research set a $535.00 price objective on Intuitive Surgical in a report on Friday, October 18th. Robert W. Baird increased their target price on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Mizuho boosted their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.